TCGA-CV-A45U-01A-12R-A24H-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.246347032
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.300
- E2F_TARGETS+0.250
- SPERMATOGENESIS+0.240
- G2M_CHECKPOINT+0.170
- GLYCOLYSIS+0.040
- WNT_BETA_CATENIN_SIGNALING+0.030
- DNA_REPAIR+0.020
- KRAS_SIGNALING_DN-0.020
- UNFOLDED_PROTEIN_RESPONSE-0.040
- NOTCH_SIGNALING-0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- MYOGENESIS-0.420
- ALLOGRAFT_REJECTION-0.380
- COAGULATION-0.380
- INFLAMMATORY_RESPONSE-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- APICAL_JUNCTION-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- INTERFERON_GAMMA_RESPONSE-0.350
- APOPTOSIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QRDT19KS | medulloblastoma | — | 0.905 |
| 2 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.879 |
| 3 | BS_QEYPFYHD | medulloblastoma | — | 0.871 |
| 4 | BS_4W68NV3M | medulloblastoma | — | 0.869 |
| 5 | BS_1TWCV047 | Embryonal tumors | — | 0.869 |
| 6 | SRR1313141 | — | E | 0.869 |
| 7 | BS_A14Z8BBK | medulloblastoma | — | 0.866 |
| 8 | 2c76906f-57a5-42b2-aa73-544814ea4657 | — | — | 0.866 |
| 9 | BS_3NWQXPQV | medulloblastoma | — | 0.859 |
| 10 | 50d87a6b-8e96-4964-9f23-53cc48c7d9ff | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |